IP Library › Granted Patent US 7,390,511
Granted Patent B2
US 7,390,511 · App. 11/709,441 · Granted Jun 24, 2008

Compositions containing vitamin E and saw palmetto

Assignee: ProEthic Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,390,511
App. No.
11/709,441
Granted
Jun 24, 2008
Kind
B2
Abstract

Mineral additives for preparing tablet compositions that comprise Vitamin E and optionally saw palmetto. The compositions are preferably formulated with a zinc compound and a selenium compound.

Claims (26)

1. A method of making a tablet comprising d-gamma, d-beta, and d-delta tocopherols (hereafter “tocopherols”) comprising: a) combining said tocopherols with a zinc component and a selenium component and optionally saw palmetto in a zinc:tocopherol weight ratio of greater than or equal to about 0.44 and a selenium:tocopherol weight ratio of greater than or equal to about 0.0059, based on the elemental weights of zinc, selenium and tocopherols, to form a combination, and b) compressing or molding said combination into a tablet, wherein, when present, said saw palmetto is present in a saw palmetto:tocopherol weight ratio of about 18.8.

2. The method of claim 1 wherein said zinc component comprises zinc gluconate.

3. The method of claim 1 , wherein said selenium component comprises chelated selenium.

4. The method of claim 1 wherein said tablet comprises from about 5 to about 50 mg. of d-gamma tocopherols and from about 1.5 to about 25 mg. of d-beta and d-delta tocopherols combined.

5. The method of claim 1 wherein said tablet comprises from about 10 to about 50 mg. of d-gamma tocopherols and from about 2 to about 20 mg. of d-beta and d-delta tocopherols combined.

6. The method of claim 1 wherein said tablet comprises from about 5 to about 50 mg. of d-gamma tocopherols and from about 1.5 to about 25 mg. of d-beta and d-delta tocopherols combined, said zinc component comprises zinc gluconate, and said selenium component comprises chelated selenium.

7. The method of claim 1 wherein said tablet comprises from about 10 to about 50 mg. of d-gamma tocopherols and from about 2 to about 20 mg. of d-beta and d-delta tocopherols combined, said zinc component comprises zinc gluconate, and said selenium component comprises chelated selenium.

8. A molded or compressed tablet comprising:

a) a mixture of oleophllic tocopherols comprising d-gamma, d-beta, and d-delta tocopherols (hereafter “tocopherols”);

b) a zinc component and a selenium component in a zinc:tocopherol weight ratio of greater than or equal to about 0.44 and a selenium:tocopherol weight ratio of greater than or equal to about 0.0059, based on the weight of elemental zinc, selenium, and tocopherols;

c) optionally saw palmetto in a saw palmetto:tocopherol weight ratio of about 18.8.

9. The tablet of claim 8 wherein said zinc component comprises zinc gluconate.

10. The tablet of claim 8 wherein said selenium component comprises chelated selenium.

11. The tablet of claim 8 wherein said tablet comprises from about 5 to about 50 mg. of d-gamma tocopherols and from about 1.5 to about 25 mg. of d-beta and d-delta tocopherols combined.

12. The tablet of claim 8 wherein said tablet comprises from about 10 to about 50 mg. of d-gamma tocopherols and from about 2 to about 20 mg. of d-beta and d-delta tocopherols combined.

13. The tablet of claim 8 wherein said tablet comprises from about 5 to about 50 mg. of d-gamma tocopherols and from about 1.5 to about 25 mg. of d-beta and d-delta tocopherols combined, said zinc component comprises zinc gluconate, and said selenium component comprises chelated selenium.

14. The tablet of claim 8 wherein said tablet comprises from about 10 to about 50 mg. of d-gamma tocopherols and from about 2 to about 20 mg. of d-beta and d-delta tocopherols combined, said zinc component comprises zinc gluconate, and said selenium component comprises chelated selenium.

15. A tablet comprising:

a) a mixture of oleophilic tocopherols comprising d-gamma, d-beta, and d-delta tocopherols (hereafter “tocopherols”);

b) a zinc component and a selenium component in an amount sufficient to stabilize said oleophilic tocopherols in said tablet, having a zinc:tocopherol weight ratio of greater than or equal to about 0.44 and a selenium:tocopherol weight ratio of greater than or equal to about 0.0059, based on the weight of elemental zinc, selenium, and tocopherols;

c) optionally saw palmetto in a saw palmetto:tocopherol weight ratio of about 18.8.

16. The tablet of claim 15 wherein said zinc component comprises zinc gluconate.

17. The tablet of claim 15 wherein said selenium component comprises chelated selenium.

18. The tablet of claim 15 wherein said tablet comprises from about 5 to about 50 mg. of d-gamma tocopherols and from about 1.5 to about 25 mg. of d-beta and d-delta tocopherols combined.

19. The tablet of claim 15 wherein said tablet comprises from about 10 to about 50 mg. of d-gamma tocopherols and from about 2 to about 20 mg. of d-beta and d-delta tocopherols combined.

20. The tablet of claim 15 wherein said tablet comprises from about 5 to about 50 mg. of d-gamma tocopherols and from about 1.5 to about 25 mg. of d-beta and d-delta tocopherols combined, said zinc component comprises zinc gluconate, and said selenium component comprises chelated selenium.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2016
From: HARVEY, BRYCE M.
To: PROETHIC LABORATORIES, LLC
Reel/Frame 037921/0417 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2016
From: MADER, V. STAN
To: PROETHIC LABORATORIES, LLC
Reel/Frame 037921/0560 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2012
From: KOWA PHARMACEUTICALS AMERICA, INC.
To: POLY PHARMACEUTICALS, INC.
Reel/Frame 027801/0292 →
CHANGE OF NAME Recorded Jan 22, 2009
From: PROETHIC PHARMACEUTICALS, INC.
To: KOWA PHARAMCEUTICALS AMERICA, INC.
Reel/Frame 022137/0158 →
Continuity (2)
Continuation 1095267400 · Sep 29, 2004
Related Publication 20070172528A1 · Jul 26, 2007